Your browser doesn't support javascript.
loading
BK polyomavirus in Kidney transplant recipients: screening, monitoring and clinical management / BK poliomavírus em receptores do transplante renal: rastreamento, monitoramento viral e manuseio clínico
Varella, Rafael Brandão; Almeida, Jorge Reis; Lopes, Patrícia de Fátima; Matos, Jorge Paulo Strogoff de; Menezes, Paulo; Lugon, Jocemir Ronaldo.
  • Varella, Rafael Brandão; Fluminense Federal University.
  • Almeida, Jorge Reis; Fluminense Federal University.
  • Lopes, Patrícia de Fátima; Fluminense Federal University.
  • Matos, Jorge Paulo Strogoff de; Fluminense Federal University.
  • Menezes, Paulo; Fluminense Federal University.
  • Lugon, Jocemir Ronaldo; Fluminense Federal University.
J. bras. nefrol ; 36(4): 529-534, Oct-Dec/2014. graf
Article in English | LILACS | ID: lil-731146
ABSTRACT
BK polyomavirus (BKPyV) is a causal agent of nephropathy, ureteral stenosis and hemorrhagic cystitis in kidney transplant recipients, and is considered an important emerging disease in transplantation. Regular screening for BKPyV reactivation mainly during the first 2 years posttransplant, with subsequent pre-emptive reduction of immunosuppression is considered the best option to avoid disease progression, since successful clearance or reduction of viremia is achieved in the vast majority of patients within 6 months. The use of drugs with antiviral properties for patients with persistent viremia has been attempted despite unclear benefits. Clinical manifestations of BKPyV nephropathy, current strategies for diagnosis and monitoring of BKPyV infection, management of immunosuppressive regimen after detection of BKPyV reactivation and the use of antiviral drugs are discussed in this review.
RESUMO
BK Poliomavírus (BKPyV) é um agente causal de nefropatia, estenose ureteral e cistite hemorrágica em receptores de transplante renal, sendo considerado uma importante doença emergente na transplantação. Rastreamento regular para reativação do BKPyV, principalmente nos dois primeiros anos pós-transplante, com subsequente redução preemptiva da imunossupressão é considerada a melhor conduta para evitar a progressão da doença, já que a eliminação ou redução da viremia é alcançada na grande maioria dos pacientes dentro de 6 meses. O uso de drogas com propriedades antivirais para os pacientes com viremia persistente tem sido tentado, embora sem benefícios claros. As manifestações clínicas da nefropatia por BKPyV, as estratégias para o diagnóstico e monitoramento da infecção por BKPyV, o manejo do regime de imunossupressão após a detecção da reativação do BKPyV e o uso de drogas antivirais são discutidas nesta revisão.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Bone Neoplasms / Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Diagnostic study / Screening study Limits: Female / Humans Language: English Journal: J. bras. nefrol Journal subject: Nephrology Year: 2014 Type: Article / Project document Affiliation country: Brazil

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Bone Neoplasms / Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Diagnostic study / Screening study Limits: Female / Humans Language: English Journal: J. bras. nefrol Journal subject: Nephrology Year: 2014 Type: Article / Project document Affiliation country: Brazil